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Abstract
Background: Previous work by our group and others has implicated a role for kinins in the
ovulatory process. The purpose of the present study was to elucidate whether endogenous
progesterone, which is an intraovarian regulator of ovulation, might be responsible for induction
of the kinin system in the ovary during ovulation. The gonadotropin-primed immature rat was used
as the experimental model, and the role of endogenous progesterone was explored using the
antiprogestin, RU486.
Results: The results of the study revealed that RU486 treatment, as expected, significantly
attenuated ovulation. Activity of the kinin-generating enzyme, kallikrein, was elevated in the ovary
in control animals prior to ovulation with peak values observed at 4 h post hCG, only to fall to low
levels at 10 h, with a recovery at 20 h post hCG. RU486 treatment had no significant effect on
ovarian kallikrein activity as compared to the control group. Total ovarian kininogen levels in
control animals increased significantly at 12–14 h after hCG – coinciding with initiation of ovulation.
Thereafter, ovarian kininogen levels fell to low levels at 20 h, only to show a rebound from 24–38
h post-hCG. RU486 treatment had no significant effect on the rise of total ovarian kininogen levels
from 12–14 h after hCG; however, from 30–40 h post hCG, RU486-treated animals had
significantly higher total ovarian kininogen levels versus control animals, suggesting that
endogenous progesterone may act to restrain elevations of kininogens in the post-ovulatory ovary.
This robust elevation of ovarian kininogen levels by RU486 was found to be primarily due to an
increase in T-kininogen, which is a potent cysteine protease inhibitor.
Conclusions: Taken as a whole, these results suggest that endogenous progesterone does not
regulate kallikrein activity or kininogens prior to ovulation, but may provide a restraining effect on
T-kininogen levels in the post-ovulatory ovary.
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Background
The kininogen-kallikrein-kinin system is well established
to be important in inflammatory processes due to its ac-
tions to induce vasodilation, prostaglandin biosynthesis,
and tissue remodeling through regulation of proteases [1–
3]. There are two types of kinins, B-kinin and T-kinin,
which are products of cleavage of the substrates B-kinino-
gen and T-kininogen, respectively [[1,2], for review]. The
enzyme kallikrein cleaves B-kininogen to B-kinin, while
the enzyme T-kininogenase cleaves T-kininogen to T-ki-
nin [3,4]. B-kinin and T-kinin have similar vasodilation
and prostaglandin regulatory actions, and are metabo-
lized by the enzyme, angiotensin-converting enzyme
[1,2]. T-kininogen, in addition to being a substrate for T-
kinin production, is a potent cysteine protease inhibitor
and has a role in tissue remodeling [5,6].
Due to its role in inflammatory processes and tissue re-
modeling functions, a number of investigators have fo-
cused on the kinin system as a possible important
mediator in the ovulatory process. Along these lines, our
group and others have demonstrated that kallikrein activ-
ity and kininogen levels in the ovary increase preceding
and at the time of ovulation in the gonadotropin-primed
immature rat [7–9]. A functional role for this activation of
the kinin system was suggested by the fact that kinin ago-
nists have been shown to induce ovulation, while con-
versely; kinin antagonists inhibit ovulation [10,11].
Additionally, work by Holland et. al. has shown that kal-
likrein (rKLK-1) gene expression increases in the ovary
preceding ovulation [9]. While evidence is mounting sup-
porting a role for the kinin system in ovulation, the pre-
cise regulators of this system in the ovary remains unclear.
In our previous study, we noticed that the elevation of ka-
llikrein activity and kininogens in the ovary preceding and
during ovulation was paralleled by an increase in ovarian
progesterone concentrations [7]. Since progesterone has
been demonstrated to be an important intraovarian regu-
lator of the ovulatory process [12,13], the aim of the
present study was to determine whether endogenous pro-
gesterone is responsible for activation of the kinin system
in the ovary during ovulation. The potent antiprogestin
compound, RU486 was used to accomplish this aim.
Results
As shown in Figure 1, PMSG-hCG induced ovulation in
control rats with peak ova released from the ovary from 24
h to 34 h after hCG administration. RU486 treatment sig-
nificantly inhibited ovulation at 20 h and 30 h (p < 0.03)
versus controls. Ovulation also appeared lower in RU486
-treated rats at 24 and 34 h after hCG as compared to con-
trols; however, due to variability this effect was not signif-
icant at these time points. Ovarian estradiol levels in
control rats were high at 0 h only to fall to basal levels
from 10 h to 38 h (Fig. 2). RU486 treatment caused a
slight but significant elevation in ovarian estradiol levels
at 30 h compared to control rats (p < 0.05). Nevertheless,
even at this time point, ovarian estradiol levels were close
to basal levels. Ovarian progesterone levels rose rapidly to
reach a peak at 12 h in control animals, followed by a fall
at 20 h to 38 h to low levels which, however, were still
higher than the initial 0 h levels (Fig 2). RU486-treated
rats had significantly attenuated peak progesterone levels
at 12 h compared to control animals (p < 0.01). Figure 3
demonstrates that ovarian kallikrein activity in control
rats was elevated prior to ovulation with peak values at 4
h, only to fall to low levels at 10 h, with a recovery at 20
h. RU486 treatment had no significant effect on ovarian
kallikrein activity as compared to controls. As shown in
Figure 4, ovarian total kininogen levels in control animals
rose in a gradual manner from 0 h to 12 h to reach peak
levels at 12 h, a time that coincides with the beginning of
ovulation. Kininogen levels then fell to low levels at 20 h
only to show a rebound from 24 to 38 h. RU486 treat-
ment had no effect on the rise of ovarian total kininogen
levels from 0 to 10 h; however, from 30–38 h RU486-
treated rats had significantly elevated ovarian total kinino-
gen levels compared to control rats (Fig 4). As illustrated
in Figure 5, T-kininogen is the major type of kininogen in
the postovulatory ovary and the elevation of total kinino-
gen levels by RU486 from 30–38 h was primarily due to
an elevation of T-kininogen levels at all time points. B-ki-
ninogen levels, on the other hand, did show a small but
significant decrease at 30 h, followed by a significant in-
crease at 34 h in RU486-treated rats versus controls.
Discussion
The present study demonstrates that treatment with the
antiprogestin compound, RU486, significantly attenuates
ovulation in PMSG-hCG-treated immature rats. This find-
ing is in agreement with previous reports in the literature
and is consistent with the hypothesis that progesterone
has a direct role in ovulation [12,14]. Along these lines,
the progesterone receptor knockout mouse has been
shown to develop follicles to the ovulatory stage, but fol-
licle rupture does not occur in these animals despite ad-
ministration of a superovulatory dose of exogenous
gonadotropins [12]. The precise genes/proteins regulated
by progesterone in the ovary to modulate ovulation re-
mains unclear. This study investigated the possible role
that endogenous progesterone may have in regulation of
the kinin system, which has been implicated as a mediator
of the ovulatory process. Several interesting observations
were yielded by the study. First, even though ovulation
was lowered by RU486 treatment, activation of the kinin
system as reflected by the elevation in ovarian kallikrein
activity and kininogen levels prior to and during ovula-
tion was not significantly affected. This suggests that pro-
gesterone may not be responsible for the elevation in
kinin system activity in the ovary observed prior to and atBMC Physiology 2002, 2 http://www.biomedcentral.com/1472-6793/2/7
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the time of ovulation, and that progesterone's modulatory
influence in the ovulatory process may be mediated
through some system other than the kinin system. Our
finding of a lack of significant effect of RU486 on ovarian
kallikrein activity during ovulation is somewhat at vari-
ance with the report of Tanaka et al. [15]. These investiga-
tors suggested a role for progesterone in the regulation of
ovarian kallikrein activity based on studies using epos-
tane, a progesterone synthesis inhibitor. In these studies,
epostane treatment inhibited ovulation and ovarian kal-
likrein activity. It should be pointed out however that
epostane, in addition to inhibiting progesterone synthe-
sis, has also been shown to strongly inhibit synthesis of
17β -estradiol, testosterone and 4-androstene-3,17-dione
in the gonadotropin-stimulated immature rat ovary, so it
is not truly specific for inhibition of progesterone synthe-
sis [16]. It should also be pointed out that the temporal
pattern for elevation of kallikrein activity differs between
the two groups. We see an early peak elevation from 0–4
h followed by a fall to low levels at 10 h and another
smaller increase at 10–12 h. Tanaka et. al. see no early in-
crease and their peak levels occur at 12–14 h post-hCG.
These differences may reflect different assay specificities as
the chromogenic substrates used in their study (D-Val-
Leu-Arg-paranitroanilide) and ours (Pro-Phe-Arg-methyl-
coumarylamide) are different. The substrate differences
could be important because different kallikreins have
been shown to have different substrate specificity [17].
The rat kallikrein gene family consists of 13 genes, of
which six are expressed in the ovary (rKLK1, rKLK3,
rKLK7, rKLK8, rKLK9 and rKLK12) [9]. In an attempt to
explain the disparate temporal pattern between the two
groups, Holland et. al. examined the gene expression pat-
tern of all six kallikrein genes in the ovary in the same go-
nadotropin-primed immature rat model used by both
groups. They found that only one gene is increased prior
to ovulation, rKLK1 or true kallikrein [9]. They also noted
that the pattern of gene expression for rKLK1 mirrored the
temporal pattern for kallikrein activity observed in our
study rather than that reported by Tanaka et. al. (e.g. it was
elevated from 0–2 h after hCG) [9]. This led the authors
to suggest that our substrate, Pro-Phe-Arg-methyl-cou-
marylamide is a more specific substrate and is detecting
true rKLK1 enzyme activity. We cannot rule out the possi-
bility that the activity of another kallikrein isoform, which
is more specifically recognized by the substrate used by
Tanaka et. al., changes after hCG, which could explain the
temporal pattern observed by Tanaka et. al. and the appar-
ent progesterone regulation they observed. However, Hol-
land et. al. did not find any other kallikrein gene elevation
prior to ovulation which would support this possibility
Figure 1
Effect of the antiprogestin RU486 upon ovulation
rate in PMSG-hCG-primed immature rats. Twenty-
three-day-old female rats were primed with 10 IU of PMSG
and 48 h later ovulation was induced with hCG (10 IU).
Either vehicle or RU486 (10 mg/kg) was administered 30
minutes prior to hCG. n = 6 rats per group. ** p < 0.03 vs.
vehicle.
Figure 2
Effect of RU486 on ovarian steroid levels in the
PMSG-hCG-primed immature rat. The model is the
same as described in Figure 1. * p < 0.05 vs. Vehicle; ** P <
0.01 vs. Vehicle.BMC Physiology 2002, 2 http://www.biomedcentral.com/1472-6793/2/7
Page 4 of 6
(page number not for citation purposes)
[9]. Finally, we did not assess for changes in one other
component of the kinin system, the bradykinin receptor.
The bradykinin B2 receptor has been demonstrated to be
localized in the ovary in theca and granulosa cells [18],
and thus regulation by progesterone at this level of the ki-
nin signaling system could be possible and cannot be ex-
cluded.
A second interesting observation from our study was that
in the post-ovulatory ovary, endogenous progesterone
might actually be acting to restrain kininogen elevations.
This suggestion is based on the finding that after ovula-
tion, RU486-treated rats exhibited a significant robust el-
evation of total ovarian kininogen levels as compared to
control animals. This elevation was principally due to a
RU486-induced increase in T-kininogen levels in the ova-
ry at 30–38 h post hCG. While the function of T-kinino-
gen in the post-ovulatory ovary is not known, T-kininogen
can be cleaved to yield the vasodilatory compound, T-ki-
nin, and in its uncleaved state, it is a potent cysteine pro-
tease inhibitor [1,2,5,6]. An important class of cysteine
proteases in the ovary that T-kininogen may regulate is
cathepsins. Cathepsins degrade type I and IV collagen, fi-
bronectin and laminin, and have been implicated to play
a role in stimulation of steroidogenesis and degradation
of extracellular matrix – events that would be occurring in
the post-ovulatory ovary as the corpus luteum is forming
[13,17–20]. In support of a possible cathepsin cysteine
protease regulatory function for T-kininogen in the ovary,
we previously reported that a strong inverse correlation
exists between T-kininogen levels and cathepsin activity in
the gonadotropin-stimulated immature rat ovary (e.g. as
T-kininogen levels increased, cathepsin activity decreased)
[7]. We believe that T-kininogen is primarily serving a
cysteine protease regulatory function in the ovary, as we
have been unable to detect T-kininogenase, the enzyme
that cleaves T-kininogen to T-kinin, in the ovary [7].
Conclusions
In conclusion, the current results do not provide support
for a role for endogenous progesterone in activation of the
kallikrein-kinin system in the ovary preceding ovulation.
Thus, progesterone modulation of ovulation most likely is
mediated by a system other than the kinin system. Intrigu-
ingly, the results suggest that endogenous progesterone
may actually be more important in regulating the kinin
system in the post-ovulatory ovary. Of significant interest,
this post-ovulatory regulation was not observed on kal-
likrein activity and only minor effects were observed on B-
kininogen, which together represent the classical kinin
pathway. Rather, the effect was observed specifically on
the newest member of the kinin/kininogen family, T-ki-
ninogen. Since we have been unable to detect T-kininoge-
nase activity in the ovary, we believe that T-kininogen is
Figure 3
Effect of RU486 on ovarian kallikrein activity in the
PMSG-hCG-primed immature rat. The model is the
same as described in Figure 1. There is no statistical differ-
ence between the groups.
Figure 4
Effect of RU486 on total ovarian kininogen levels in
the PMSG-hCG-primed immature rat. The model is
the same as described in Figure 1. * p < 0.05 vs. Vehicle; ** p
< 0.01 vs. Vehicle.BMC Physiology 2002, 2 http://www.biomedcentral.com/1472-6793/2/7
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functioning primarily as a cysteine protease inhibitor in
the ovary. Thus, endogenous progesterone restrainment
of T-kininogen in the post-ovulatory ovary could be a
mechanism for modulation of cysteine protease activity in
the post-ovulatory ovary, thereby facilitating the extensive
tissue remodeling that is known to occur after ovulation.
Additional studies are underway in our laboratory to fur-
ther explore this possibility.
Materials and Methods
Animals
Immature 23-day-old female Sprague Dawley rats (Holtz-
man, Madison, WI) were given PMSG at 0800 h. Forty-
eight hours later, the animals were given hCG (10 IU, s.c.
in saline; Sigma, St. Louis, MO) to induce ovulation. Thir-
ty minutes prior to hCG injection, either vehicle or the an-
tiprogestin RU486 (10 mg/kg in ethylene glycol ip;
Roussel UCLAF, Romanville, France) was administered.
In the PMSG-hCG induction model, mature follicles first
begin to ovulate at 12–15 h, with peak number of ova ap-
pearing in the oviducts at 24–30 h [7]. To access the role
of the kinin system in the ovulatory process, groups of an-
imals were killed at various time points after hCG treat-
ment; the ovaries were removed to determine ovulation
and to measure the various components of the kininogen-
kallikrein-kinin system. After removal, the ovaries were
cleaned of fat, snap frozen in liquid nitrogen, and stored
at -70°C until the various assays were performed. All pro-
tocols involving animal use in this study were approved
by our Institutional committee for the care and use of an-
imals in research (CAURE).
Determination of ovulation
To determine ovulation, the animals were killed by decap-
itation and the oviducts were removed, pressed between
two microscope slides, and examined under a microscope
for the presence of ova as described previously [7].
Preparation of Tissue Homogenate
Ovaries excised from each animal were homogenized us-
ing a Dyna-Mix (Fisher Scientific, Pittsburg, PA) in 400 µl
of 50 mM ice-cold PBS, pH 7.4. The homogenates were
centrifuged at 4°C at 20,000 ×  g for 20 min. The superna-
tants were then assayed as described below.
Determination of Kininogens
Measurements of kininogen levels were performed as de-
scribed previously by our laboratory using the protocols
described by Barlas et al. [7,21]. Total kininogens. Plasma
(100 µl) or tissue homogenate (100 µl) was incubated
with 900 µl of 0.03 N HCl at 37°C for 15 min to destroy
kininase activity. After neutralization with 25 µl of 1 M
NaOH, 25 µl of 5 mg/ml trypsin was added (final concen-
tration of trypsin was 1 mg/ml) and incubated at 37°C for
1 h to liberate kinins from the kininogens. The reaction
was stopped by heating at 100°C for 10 min. The liberated
kinins were quantified according to the RIA method of
Greenbaum and Okamoto [2]. An aliquot of the sample
(100 µl) was incubated at 4°C with 400 µl of 125I-labeled
bradykinin (BK) and 100 µl of BK polycolonal antibodies,
which were raised from the rabbit and able to recognize
all kinins. After 2–24 h, 1% of bovine gamma globulin
and 25% polyethylene glycol were added, respectively, to
separate bound and free kinins. Radioactivity was counted
by a gamma counter. Total kininogen was expressed as µg/
mg protein of BK equivalents.
T-kininogen
After trypsin digestion, plasma was treated with an equal
volume of 30 % trifluoroacetic acid (TFA). The superna-
tant, after centrifugation for 10 min at 3,000 rpm, was ap-
plied to a C-18 extraction column previously primed with
5 ml methanol and 5 ml of 1% TFA. After an initial wash
with 1% TFA, the kinins were eluted with 1.5 ml of 50%
acetonitrile in 1 % TFA. The elute was evaporated to dry-
ness on a Speed Vac centrifuge, redissolved in 40 µl of dis-
tilled water, and applied to an HPLC column equilibrated
with a mixture of 18% acetonitrile and 82% triethylam-
monium formate (v/v), pH 4.0. Fractions (14 ml/2 min)
were collected and subjected to RIA. T-kinin (µg kinin
equiv./mg protein) = [Total kinins released by trypsin] ×
% T-kinin in total kinin eluted. BK-kininogen was estimat-
Figure 5
Species of kininogens in the ovary after RU486 treat-
ment in the PMSG-hCG-primed immature rat. The
model is the same as described in Figure 1. *p < 0.05 vs. Vehi-
cle; ** p < 0.01 vs. Vehicle.BMC Physiology 2002, 2 http://www.biomedcentral.com/1472-6793/2/7
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ed by subtracting the amounts of T-kinin released from T-
kininogen by trypsin from the amount of kinins released
for total kininogen.
Assay of Kallikrein
Kallikrein activity was measured as described previously
by our laboratory [7,22]. Briefly, tissue homogenate was
incubated with a substrate, Pro-Phe-Arg-methylcoumary-
lamide (MCA), in 0.1 M Tris-HCl buffer containing 0.15
M NaCl., pH 8.0. The initial hydrolysis of the substrate for
the first 5 min is recorded. One unit of enzyme activity of
kallikrein releases amino methylcoumarin (AMC) from
the substrate at a rate of 1 nM/5 min. The hydrolysis of
AMC was measured using a fluorescence spectrophotom-
eter with excitation at 370 nm and emission at 460 nm.
Statistical Analysis
The results given in the text are expressed as means ± SEM.
Six rats were used per group and the experiments were re-
peated three times. The differences between experimental
groups were analyzed using the student t-test; p < 0.05 was
considered significant.
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